CL2022002699A1 - Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. - Google Patents
Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.Info
- Publication number
- CL2022002699A1 CL2022002699A1 CL2022002699A CL2022002699A CL2022002699A1 CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1 CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- multiple sclerosis
- tyrosine kinase
- kinase inhibitor
- relapsing multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002699A1 true CL2022002699A1 (es) | 2023-03-31 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002699A CL2022002699A1 (es) | 2020-04-03 | 2022-09-30 | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173740A1 (en) * | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| TW202508592A (zh) * | 2023-05-16 | 2025-03-01 | 美商建南德克公司 | 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR20170033358A (ko) | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| KR102635949B1 (ko) | 2017-05-18 | 2024-02-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도 |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| EP3849559A4 (en) * | 2018-09-12 | 2022-06-01 | Denovo Biopharma LLC | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF |
| TW202042815A (zh) | 2019-01-22 | 2020-12-01 | 美商建南德克公司 | 使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 |
| WO2021173740A1 (en) | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
-
2021
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4125906A1 (en) | 2023-02-08 |
| TW202203925A (zh) | 2022-02-01 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| BR112022019846A2 (pt) | 2022-11-22 |
| AU2021249129A1 (en) | 2022-10-20 |
| CN115916205A (zh) | 2023-04-04 |
| WO2021202825A1 (en) | 2021-10-07 |
| JP2023520469A (ja) | 2023-05-17 |
| IL296990A (en) | 2022-12-01 |
| TWI907406B (zh) | 2025-12-11 |
| MX2022012310A (es) | 2022-10-27 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| MX2022012285A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| DK0735868T3 (da) | Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| FI3972603T3 (fi) | Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää | |
| BR112023025459A2 (pt) | Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| MX2024001540A (es) | Inhibidores para coronavirus. | |
| CO2022014992A2 (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| UY39864A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| BR0111158A (pt) | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| BR112022024751A2 (pt) | Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. |